EVH
Evolent Health, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 24 Evolent Health reported a significant year-over-year decline in reve…
- Jun 30 ▼ Truist Securities downgrades
- Jul 23 ▼ Citigroup downgrades
- Aug 6 Evolent Health reported Q2 2026 revenue of $652.5M, up 46.9% YoY, bu…
- Aug 11 ▲ Citigroup upgrades
- Aug 26 ▼ 1 insider sell $329.5K at $5.00
- Nov 5 ▲ Earnings: EVH Q3 2026 Earnings: EPS $0.06 (+13.2% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $329.5K.
- InstitutionsBULLISH
Q3 2026: 27 added (1 new), 15 trimmed or exited.
- AnalystsBULLISH
14 of 18 rate it Buy or better. Median target $6.00 (+24%).
- Short sellersSTEADY
Short interest −10.9% to 10.61M shares. 7.0 days to cover, ≈9.4% of shares.
- TrendUPTREND
14% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | ADD | $18.6M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | $11.7M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $7.2M |
| MORGAN STANLEY | NEAR_EXIT | $6.9M |
| Qube Research & Technologies Ltd | DOUBLED | $5.3M |
| Hudson Bay Capital Management LP | ADD | $5.2M |
| Walleye Capital LLC | ADD | $3.9M |
| JPMORGAN CHASE & CO | DOUBLED | $3.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is inside the target range. Median implies +24%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Oppenheimer MAINTAIN | Outperform |
| Nov 5, 2026 | Needham MAINTAIN | Buy |
| Aug 18, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 17, 2026 | TD Cowen MAINTAIN | Buy |
| Aug 12, 2026 | Truist Securities MAINTAIN | Hold |
| Aug 11, 2026 | Citigroup UPGRADE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
McCarthy Daniel Joseph PRESIDENT Aug 26, 2026 | SELL | $329.5K |
Shams Aammaad Chief Accounting Officer Jul 1, 2026 | AWARD | 28,790 sh |
McCarthy Daniel Joseph PRESIDENT Jul 1, 2026 | AWARD | 302,585 sh |
Blackley Seth Chief Executive Officer Jul 1, 2026 | AWARD | 446,102 sh |
McCarthy Daniel Joseph PRESIDENT Jul 1, 2026 | TAX W/H | $26.3K |
Blackley Seth Chief Executive Officer Jul 1, 2026 | TAX W/H | $59.1K |
Weinberg Jonathan General Counsel Jul 1, 2026 | TAX W/H | $15.2K |
Weinberg Jonathan General Counsel Jul 1, 2026 | AWARD | 43,055 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 0 bullish · 2 bearish · 2 mixed · 4 neutral- BEARISH SC 13G/ANov 16, 2026
Cadian Capital Management filed an amended Schedule 13G disclosing a 0.5% passive stake (509,464 shares) in Evolent Health as of September 30, 2026, down from a prior above-5% position. This follows a similar reduction by Rubicon Funds and Adam Boehler three days earlier, signaling continued…
🔒 Fresh report (last 24h), subscribers only
- BEARISH SC 13G/ANov 13, 2026
Rubicon Funds and Adam Boehler filed an amended Schedule 13G disclosing that they have ceased to…
The drop below 5% removes the group from future 13G filing obligations, reducing transparency into their ongoing trading. Monitor for further insider selling or a potential conversion to a 13D if…
- NEUTRAL 8-KNov 5, 2026
Evolent Health reported Q3 2026 revenue of $725.4M, up 51% YoY, and a GAAP net loss of $23.6M…
Revenue growth is strong from new oncology contracts, but the rising medical expense ratio (93.0% vs 85.0%) and declining Adjusted EBITDA margin signal cost pressure. The raised EBITDA guidance…
- NEUTRAL PRESS-RELEASENov 5, 2026
Evolent Health reported Q3 2026 revenue of $725.4M, up 51% YoY, and adjusted EPS of $0.06, in line…
Revenue growth is strong but margin compression from rising medical costs is the key watch item. The raised EBITDA guidance suggests management sees some stabilization; monitor next quarter's…
All EVH filing & press-release reports (8)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportJul 8, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportFeb 24, 2026